16 Apr 2021 --- ADM has reached a new milestone in advancing potential therapies for metabolic health conditions, such as diabetes, through pro- and postbiotics. Hailed as a “world-first” in probiotics, researchers identified the molecule lipoteichoic acid (LTA) as the compound that may be behind the efficacy of the company’s Bifidobacterium animalis subsp. lactis CECT 8145 (BPL1).
